Press Releases

PTC is committed to serving the interests of all our stakeholders.
Pam & Kelsey
Living with PKU, United States

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Jan 28, 2016
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Jan. 28, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that management will present a company update at the following conferences: Leerink Partners' 5th Annual Global Healthcare Conference, on Thursday, February 11th at 1:25 p.m.
Read More
Jan 08, 2016
PTC Completes Rolling NDA Submission to FDA and Submits Phase 3 ACT DMD Clinical Trial Results to EMA for Translarna™ (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy
SOUTH PLAINFIELD, N.J. , Jan. 8, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced the completion of its rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ (ataluren), an oral, first-in-class, protein
Read More